Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FourLight-3: PF-07220060 + letrozole versus CDK4/6 inhibitor + letrozole in first-line HR-positive, HER2-negative advanced/metastatic breast cancer
NL-OMON60187Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atirmociclib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jul 2025; status: active, not recruiting.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60187.